Sequenom to Provide Quantitative Gene Expression Services to the Immune Tolerance Network.

MassARRAY Platform Selected as Only Technology to Meet Stringent Assay Requirements

SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM) today announced that it will provide quantitative gene expression (QGE) services to the Immune Tolerance Network (ITN), a collaborative research organization that solicits, develops, implements and assesses clinical strategies and biological assays for the purposes of inducing, maintaining and monitoring tolerance in humans for kidney, liver and islet transplantation, autoimmune diseases, and allergy and asthma. Financial terms of the contract were not disclosed.

"Our choice of Sequenom's MassARRAY[R] QGE technology and services is based on testing that demonstrated a high level of accuracy and sensitivity for quantitative gene expression evaluation. Sequenom's services also meet the ITN's assay requirements for reproducibility and quality assurance. Additionally, we are very impressed with the Sequenom scientific team, who demonstrated a thorough understanding of the field and the challenges inherent in gene expression analysis of human clinical samples," said Vicki Seyfert-Margolis, Ph.D., Executive Director, Assay Tolerance Group for ITN.

"Once again, the high sensitivity of the MassARRAY platform, which has enabled the identification of new disease-relevant genes where other systems have failed, is recognized by another world-leading clinical research organization. The ITN, focused on immune tolerance, has joined a growing list of prominent collaborators that rely on our MassARRAY technology for clinical applications," said Harry Stylli, Ph.D., Chief Executive Officer of Sequenom. "Collaborations such as this demonstrate the high-value proposition of the MassARRAY platform and the QGE multiplexing assay, which allows for high levels of multiplexing and significantly reduces cost per data-point."

About the Immune Tolerance Network

Headquartered at the University of California, San Francisco, the Immune Tolerance Network (ITN) is an international collaboration of researchers that conducts clinical research of new immune tolerance therapies -- highly targeted treatments that prevent harmful immune responses, while leaving the protective immune response unhindered. Targeting autoimmune diseases, islet, kidney and liver transplantation and allergy and asthma, the ITN is supported by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases, and partners with the Juvenile Diabetes Research Foundation for type 1 diabetes research. More information is available at www.immunetolerance.org.

About Sequenom

Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, livestock and agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company's proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.

Sequenom([R]) and MassARRAY([R]) are trademarks of SEQUENOM, Inc.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the services to be provided by the Company to the ITN, MassARRAY technology's ability to meet stringent assay requirements, and the Company's intentions regarding development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with new assay designs, new technology and product development and commercialization particularly for new technologies such as non-invasive prenatal diagnostics, reliance upon the collaborative efforts of other parties such as the ITN, research and development progress, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company's SEC (U.S. Securities and Exchange Commission) filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, most recently periodic quarterly report, and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.